Adding Venetoclax to DA-EPOCH-R Leads to Excess Deaths in Double-Hit Lymphoma

Adding venetoclax to chemoimmunotherapy results in excess treatment-related deaths in patients with double-hit lymphoma, a new study suggests.

Related Keywords

United States ,Boston ,Massachusetts ,American ,Jeremys Abramson , ,American Society Of Hematology ,American Society Of Hematology Annual Meeting ,Hospital Cancer Center ,Hematology Annual ,Cancer Therapy Advisor ,Massachusetts General Hospital Cancer Center ,